Informa PLC

M&A Activity • Jun 1, 2022

National Storage Mechanism | Additional information

RNS Number : 4796N

Informa PLC

01 June 2022

Informa PLC Press Release

1 June 2022

Completion of £1.9bn Pharma Intelligence agreement

Portfolio re-balancing and accelerating shareholder returns

Informa (LSE: INF.L), the international Academic Markets, B2B Markets and Digital Services Group today confirmed the completion of its £1.9bn Pharma Intelligence agreement which forms part of the 2021-2024 Growth Acceleration Plan II ("GAP II").

The agreement announced on 10 February sees the Group receive c.£1.7bn in cash before tax deductions and a c.15% shareholding in the ongoing business. This c.15% equity interest ranks pari passu with Warburg Pincus' equity (the acquirer), enabling Informa to realise significant value today, whilst sharing in the future value created from further growth and portfolio expansion.

Re-balancing the Group's portfolio is a key part of Informa's GAP II programme, a four-year plan designed to create a more focused, higher growth business, with digital and data excellence at its core. Following Pharma Intelligence, the Group is now reviewing its Financial Intelligence portfolio.

The Group will provide an update on GAP II Shareholder Returns within its AGM Trading Update on 16 June 2022. Since March, the Group has completed c.£257m of its current £300m share buyback commitment, at a weighted average price of 581p, leading to the cancellation of c.44m shares.

Enquiries
Stephen A. Carter, Chief Executive	+44 (0) 20 8052 0400
Gareth Wright, Finance Director	+44 (0) 20 8052 0400
Richard Menzies-Gow, Director of IR & Communications	+44 (0) 20 8052 2787
Tim Burt / Simon Duke - Teneo	+44 (0) 20 7240 2486

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DISBFLLXLELBBBF